The new guidelines for the management of pulmonary arterial hypertension (PAH) in adults published by The American College of Chest Physicians (CHEST) is free to view in this month’s online issue of the journal CHEST for patients and clinicians alike. Full access to the study, entitled “Pharmacologic Therapy…
News
Some of the most difficult-to-treat patients with pulmonary hypertension are those with chronic thromboembolic pulmonary hypertension (CTEPH). These patients are in the most severe category of pulmonary hypertension: World Health Organization (WHO) Group 4. CTEPH patients have curative potential if they have no resectable lesions or contraindications…
Endothelin-receptor antagonists (ERAs), recently discussed on Pulmonary Hypertension News as being effective for treating pulmonary hypertension, have been a standard part of clinician’s portfolios along with phosphodiesterase type 5 inhibitors and calcium channel blockers. The common definition for “treating pulmonary…
Pulmonary hypertension (PH) on its own is burdensome to the patients it afflicts, but when PH is combined with other diseases, the conditions can be devastating. In the case of pulmonary fibrosis and emphysema…
Pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH) are not popular topics of media coverage and popular conversation in the way that cancer and heart disease are. Despite increasing numbers of people diagnosed with PH/PAH worldwide, pulmonary hypertension has been a historically neglected disease. Which is a bit puzzling, since…
Early detection of chronic thromboembolic pulmonary hypertension (CTEPH) is vital to addressing and potentially preventing the most common cause of severe pulmonary hypertension. A number of clinical diagnostic parameters have been studied and effectively practiced, but detection can extend beyond the doctor’s office. A study…
A recent article on the University of New Mexico’s athletics news page profiles the return of a former UNM alumnus who earned both her education and legacy as a star soccer player for the school who is now helping to launch a new Pulmonary Hypertensive clinic and program at the…
More often than not, risk factors for and development rates of cardiovascular diseases vary according to race and ethnicity, and pulmonary arterial hypertension due to systemic sclerosis is no exception. A study from Johns Hopkins University, appearing in the journal European Respiratory Journal, identified the…
A recent blog article entitled, “How High Is too High – Altitude and PAH” from pulmonology specialist Jeremy P. Feldman, published on the blog Pulmonary Hypertension R.N. is encouraging patients with pulmonary arterial hypertension to consult their physicians prior to airplane travel and exposure to high altitudes, noting that physicians can help…
Pulmonary hypertension can be a devastating disease, especially when it impacts infants and children. A new study in Pediatrics from Nagasaki University and Nagasaki University Hospital in Japan and Khanh Hoa General Hospital and Health Service in Vietnam found high rates of mortality from pulmonary hypertension in…
As new medications for pulmonary hypertension are approved and marketed, it is important to evaluate their efficacy, both absolutely and relative to tried-and-true products. Macitentan, marketed under the name Opsumit by Actelion, is approved to treat pulmonary arterial hypertension patients under the World Health Organization classification of…
The Pulmonary Hypertension Association (PHA) recently nominated Stephen L. White as Chair of the Board of Trustees of the organization, after years of his involvement in the PHA’s ongoing national effort to prevent and cure pulmonary hypertension (PH), according to a recent press release. He already serves as chair of…
